Dermatologic Toxicities in Epidermal Growth Factor Receptor and Multikinase Inhibitors

Targeted therapies have produced significant treatment advances for patients diagnosed with a variety of tumor types. These therapies are associated with unique dermatologic toxicities that may hamper treatment efforts and cause significant discomfort for patients. Prevention and management of these...

Descripción completa

Detalles Bibliográficos
Autores principales: Eaby-Sandy, Beth, Grande, Carolyn, Viale, Pamela Hallquist
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press 2012
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4093313/
https://www.ncbi.nlm.nih.gov/pubmed/25031940
_version_ 1782325701015240704
author Eaby-Sandy, Beth
Grande, Carolyn
Viale, Pamela Hallquist
author_facet Eaby-Sandy, Beth
Grande, Carolyn
Viale, Pamela Hallquist
author_sort Eaby-Sandy, Beth
collection PubMed
description Targeted therapies have produced significant treatment advances for patients diagnosed with a variety of tumor types. These therapies are associated with unique dermatologic toxicities that may hamper treatment efforts and cause significant discomfort for patients. Prevention and management of these toxicities can allow patients to remain on therapy and hence receive maximum clinical benefit from the drug.
format Online
Article
Text
id pubmed-4093313
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Harborside Press
record_format MEDLINE/PubMed
spelling pubmed-40933132014-07-16 Dermatologic Toxicities in Epidermal Growth Factor Receptor and Multikinase Inhibitors Eaby-Sandy, Beth Grande, Carolyn Viale, Pamela Hallquist J Adv Pract Oncol Review Article Targeted therapies have produced significant treatment advances for patients diagnosed with a variety of tumor types. These therapies are associated with unique dermatologic toxicities that may hamper treatment efforts and cause significant discomfort for patients. Prevention and management of these toxicities can allow patients to remain on therapy and hence receive maximum clinical benefit from the drug. Harborside Press 2012 2012-05-01 /pmc/articles/PMC4093313/ /pubmed/25031940 Text en Copyright © 2012, Harborside Press http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited and is for non-commercial purposes.
spellingShingle Review Article
Eaby-Sandy, Beth
Grande, Carolyn
Viale, Pamela Hallquist
Dermatologic Toxicities in Epidermal Growth Factor Receptor and Multikinase Inhibitors
title Dermatologic Toxicities in Epidermal Growth Factor Receptor and Multikinase Inhibitors
title_full Dermatologic Toxicities in Epidermal Growth Factor Receptor and Multikinase Inhibitors
title_fullStr Dermatologic Toxicities in Epidermal Growth Factor Receptor and Multikinase Inhibitors
title_full_unstemmed Dermatologic Toxicities in Epidermal Growth Factor Receptor and Multikinase Inhibitors
title_short Dermatologic Toxicities in Epidermal Growth Factor Receptor and Multikinase Inhibitors
title_sort dermatologic toxicities in epidermal growth factor receptor and multikinase inhibitors
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4093313/
https://www.ncbi.nlm.nih.gov/pubmed/25031940
work_keys_str_mv AT eabysandybeth dermatologictoxicitiesinepidermalgrowthfactorreceptorandmultikinaseinhibitors
AT grandecarolyn dermatologictoxicitiesinepidermalgrowthfactorreceptorandmultikinaseinhibitors
AT vialepamelahallquist dermatologictoxicitiesinepidermalgrowthfactorreceptorandmultikinaseinhibitors

Ejemplares similares